慢性乙型肝炎识别与监测项目改善整合医疗计划中的诊疗
该研究回顾性分析了Kaiser Permanente Northern California肝病关怀项目8年数据,14,630例符合监测标准的慢性乙型肝炎患者中9,373例(64.1%)入组。入组患者接受≥80%推荐影像监测的比例为41.5%,未入组者为10.9%(风险比=3.8;P<0.001);入组患者肝癌确诊时巴塞罗那分期0/A期比例为95.9%,未入组者为74.6%(P<0.001)。
要点
- 肝病关怀项目入组患者接受≥80%推荐影像监测的比例为41.5%,未入组者为10.9%(风险比=3.8;P<0.001)。
- 两组约63%符合治疗条件患者接受药物治疗,入组者完全依从率为72.3%,未入组者为63.4%(P<0.001)。
- 197例肝癌患者中,入组者接受推荐监测影像更频繁(71.4% vs 53.8%,P<0.05),0/A期诊断比例更高(95.9% vs 74.6%,P<0.001)。
核心结论
- 在整合医疗系统中,针对慢性乙型肝炎患者的系统性监测与管理项目似乎对流程和临床终点均有益。
研究设计与样本
- 回顾性队列研究,纳入Kaiser Permanente Northern California 2012年建立的肝病关怀项目中所有符合指南肝癌监测标准的慢性乙型肝炎患者,报告项目运行最初8年结果。
主要发现
- 自项目启动以来,14,630例患者符合研究标准,其中9,373例(64.1%)入组肝病关怀项目。
- 入组患者中41.5%接受≥80%推荐影像监测,未入组患者中为10.9%(风险比=3.8;P<0.001)。
- 两组约63%符合治疗条件患者接受药物治疗,入组患者完全依从率为72.3%,未入组患者为63.4%(P<0.001)。
- 197例发生肝癌的患者中,入组患者接受推荐监测影像更频繁(71.4% vs 53.8%,P<0.05)。
- 入组患者肝癌确诊时巴塞罗那临床肝癌分期0/A期比例为95.9%,未入组患者为74.6%(P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Optimal management of patients with chronic hepatitis B (CHB) requires surveillance for hepatocellular carcinoma (HCC) and identification of antiviral therapy candidates, but few dedicated CHB surveillance models have been described. Kaiser Permanente Northern California developed a systematic CHB surveillance and management program in 2012. We report the results of the program's performance over the initial 8-year period. METHODS: We conducted a retrospective cohort study of all patients with CHB meeting guideline criteria for HCC surveillance. Eligible patients were invited into the Kaiser Permanente Northern California Liver Care Program (LCP), wherein patients receive reminders to obtain semiannual laboratory and imaging surveillance, which are reviewed by nurse practitioners. Treatment-eligible patients are provided with antiviral medications. RESULTS: Since its inception, 14,630 patients met study criteria, and 9,373 (64.1%) enrolled in the LCP. Adherence to imaging recommendations was higher in the LCP-managed group (41.5% of patients in the LCP received ≥80% of recommended imaging compared with 10.9% among patients not enrolled [risk ratio = 3.8; P < 0.001]). Approximately 63% of treatment-eligible patients in both groups received medication, although full-adherence rates were higher in patients managed in the LCP (72.3% vs 63.4%, respectively, P < 0.001). Among the 197 patients who developed HCC, recommended surveillance imaging was performed more frequently among LCP-managed patients (71.4% vs 53.8%, respectively, P < 0.05) who were also significantly more likely to be diagnosed at Barcelona Clinic Liver Cancer Stage 0/A (95.9% vs 74.6%; P < 0.001). DISCUSSION: In this integrated healthcare system, a systematic program for surveilling and managing patients with CHB seemed beneficial for both process and clinical endpoints.
引用
- Chai KP, Saxena V, Seo S, et al. A Chronic Hepatitis B Identification and Surveillance Program Improves Care in an Integrated Health Plan. Am J Gastroenterol. 2024. PMID: 39364887. doi:10.14309/ajg.0000000000003116
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。